|
May 17
|
Erasca restructures; Novartis moves to complete MorphoSys deal
|
|
May 10
|
MorphoSys (ETR:MOR) shareholders have earned a 228% return over the last year
|
|
Apr 29
|
MorphoSys AG Reports First Quarter 2024 Financial Results
|
|
Apr 24
|
MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
|
|
Apr 12
|
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
|
|
Apr 11
|
Novartis (NVS) to Undertake Job Cuts in Development Department
|
|
Apr 11
|
MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
|
|
Apr 11
|
UPDATE 3-Novartis begins tender offer for cancer-focused MorphoSys
|
|
Mar 22
|
MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
|
|
Mar 15
|
MorphoSys AG (NASDAQ:MOR) Q4 2023 Earnings Call Transcript
|
|
Mar 13
|
MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
|
|
Mar 11
|
The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys
|
|
Mar 8
|
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
|
|
Mar 7
|
Invitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024
|
|
Mar 4
|
MorphoSys AG Unsponsored ADR (MOR) is a Great Momentum Stock: Should You Buy?
|
|
Nov 2
|
MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting
|
|
Oct 22
|
Institutional investors have a lot riding on MorphoSys AG (ETR:MOR) with 49% ownership
|
|
Sep 5
|
Is MorphoSys AG (MOR) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap
|